All In Biotech

Drug Trial Radar · NCT01229761

Study to Improve Survival Among HIV-Exposed Infants in Botswana

A Randomized Study of Cotrimoxazole Prophylaxis and Longer Breastfeeding Duration to Improve Survival Among HIV-Exposed Infants in Botswana

Last checked: Nov 19, 2026Latest source record: Sep 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,724 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,724

Planned (sponsor's estimate)

Start

May 2011

Primary completion

Mar 2015

Study completion Oct 2018

Sponsor

Lead sponsor
Harvard School of Public Health (HSPH)Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Harvard Medical School (HMS and HSDM); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Oct 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find ways to improve infant health and survival among infants whose mothers are HIV-infected but who do not themselves have HIV.

Conditions

  • HIV Infections
  • Neutropenia
  • Anemia

Interventions

  • cotrimoxazole prophylaxisDrug

    100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months

  • cotrimoxazole placeboDrug

    100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months

  • exclusive breastfeeding until 6 months of ageBehavioral

    Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.

  • breastfeeding for 12 monthsBehavioral

    Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: 18 months of age

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Princess Marina Hospital

    Gaborone, Botswana

  • Athlone Hospital

    Lobatse, Botswana

  • Scottish Livingstone Hospital

    Molepolole, Botswana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.